预约演示
更新于：2025-07-15
Finasteride
非那雄胺
更新于：2025-07-15
概要
基本信息
简介Finasteride，商业名称为PROSCAR®，是一种5α-还原酶抑制剂药物，主要用于治疗男性前列腺增生症（BPH），改善症状、降低急性尿潴留的风险以及降低需要手术（包括经尿道前列腺电切术和摘除前列腺）的风险。这种药物于1992年在美国获得首次批准，由默克公司生产。PROSCAR (finasteride)是一种合成的4-氮杂甾体化合物，是一种特异性的类固醇II型5α-还原酶抑制剂，可抑制细胞内的酶将雄激素睾酮转化为5α-二氢睾酮（DHT）。 |
药物类型 小分子化药 |
别名 (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide、Finasteride (JAN/USP/INN)、非那雄胺（奎安） + [47] |
作用方式 抑制剂 |
作用机制 5α-reductase抑制剂(类固醇5α还原酶抑制剂) |
最高研发阶段批准上市 |
首次获批日期 美国 (1992-06-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H36N2O2 |
InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N |
CAS号98319-26-7 |
关联
143
项与 非那雄胺 相关的临床试验NCT06944145
New Treatment Strategies and Epigenetic Biomarker for Management of BPH
NCT06826001
COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA
TCTR20240926001
Efficacy and safety of different doses of topical finasteride in the treatment of male androgenetic alopecia
100 项与 非那雄胺 相关的临床结果
登录后查看更多信息
100 项与 非那雄胺 相关的转化医学
登录后查看更多信息
100 项与 非那雄胺 相关的专利（医药）
登录后查看更多信息
4,296
项与 非那雄胺 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
The impact of cannabis use on local anesthetic dosing during hair restoration surgery: a case report, proposed mechanisms, and clinical recommendations
Review
作者: Keene, Sharon A. ; Gupta, Aditya K. ; Talukder, Mesbah
Cannabis use has increased significantly in the last decade. This article presents a case where a patient needed more local anesthetic (LA) than usual to induce effective anesthesia during hair transplant surgery. The reason cannabis users often need more LA is poorly understood. One possibility is that cannabis withdrawal effect makes patients more sensitive to pain and stress. Additionally, vasodilatory property of cannabis may speed up LA clearance from the application site. The interactions of two major cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), with cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), and transient receptor potential vanilloid 1 (TRPV1) receptors are also complex. Furthermore, CBD and THC function as cytochrome P450 enzyme inhibitors potentially impacting systemic metabolism. When planning to administer LA during hair restoration surgery in cannabis users, clinicians should obtain a detailed history of prior consumption (type of cannabis, frequency, dosage). Preoperative planning should consider the anticipated duration of surgery and calculate the maximum safe LA dose to avoid the risk of toxicity. Also, patients should be carefully monitored for vital signs during surgery. If a patient requires frequent re-injection to remain pain free, the surgeon may need to re-assess the surgical plan to avoid toxicity.
2025-09-01Genes & Diseases
Integrating spatial transcriptomics and single-cell RNA-sequencing reveals epithelial cell alterations in benign prostatic hyperplasia following finasteride treatment
Article
作者: Liu, Jican ; Xu, Huan ; Shen, Yanting ; Dai, Liyang ; Wu, Zhenqi ; Li, Huifeng ; Fei, Xiawei ; Zhu, Ting ; Wang, Zhong
2025-09-01Translational Oncology
Identification and validation of synergistic drug strategies targeting macrophage polarization in triple-negative breast cancer via single-cell transcriptomics and deep learning
Article
作者: Wang, Hui ; Gul, Samina ; Li, Liang ; Pang, Jianyu ; Yang, Wenhao ; Tang, Yuheng ; Tang, Wenru ; Xie, Xiaoli ; Qi, Qi ; Yingjie, Sun ; Shi, Jialin ; Chen, Yongzhi
Triple-negative breast cancer (TNBC) presents therapeutic challenges due to its immunosuppressive tumor microenvironment (TME) and limited targeted options. Analyzing scRNA-seq data from 24 TNBC patients using integrated transcriptomics, machine-learning, and pseudo-time trajectory mapping, we developed a macrophage differentiation-based classifier (MMDCSS) (CD93, CHI3L1, ZBTB20) with remarkable prognostic accuracy (C-index: 0.929, 3-year AUC: 0.907). Computational pharmacology identified finasteride as a ZBTB20 modulator (binding energy:7.7 kcal/mol) capable of reversing tumor-induced M2 macrophage polarization. Finasteride significantly enhanced doxorubicin efficacy ex vivo and in vivo by reprogramming the TME, reducing M2 macrophage infiltration while promoting an M1 phenotype. Mechanistically, finasteride upregulated ZBTB20, counteracting TNBC-mediated suppression of this M1-associated transcription factor. Our findings establish ZBTB20 as a key regulator of macrophage polarization in TNBC and introduce finasteride as a clinically viable agent to reverse TME immunosuppression. Targeting macrophage polarization via ZBTB20 modulation, particularly by repurposing finasteride, offers a promising therapeutic strategy for TNBC with immediate translational potential.
100 项与 非那雄胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 雄激素脱发 | 美国 | 1997-12-19 | |
| 前列腺增生症 | 美国 | 1992-06-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 男性雄激素源性脱发 | 临床3期 | 比利时 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 德国 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 匈牙利 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 俄罗斯 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 西班牙 | 2016-08-02 | |
| 血尿 | 临床2期 | 加拿大 | 2008-03-01 | |
| 血精症 | 临床2期 | 加拿大 | 2008-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 脊髓损伤 testosterone | estradiol | dihydrotestosterone | 12 | High-dose Testosterone + Finasteride | 範顧壓鹹遞簾遞襯築觸(鏇餘醖壓遞觸選顧鹽壓) = reduced more than vehicle+placebo at 12 months 憲簾糧齋獵構選積構蓋 (範艱範獵夢壓願製廠鏇 ) 更多 | 积极 | 2024-12-11 | |
临床2期 | 43 | 蓋鬱觸範憲憲構鑰衊獵 = 鏇獵選蓋構遞顧餘鹹窪 艱構鬱糧鹽窪蓋醖艱衊 (積醖壓築鑰繭窪築窪製, 鑰鹽餘鬱遞築廠鹹窪醖 ~ 構糧網製鹹窪鹹鏇憲鑰) 更多 | - | 2024-11-13 | |||
临床2期 | 43 | 網齋簾簾鬱廠廠膚鬱範(獵鹹蓋鹹範鏇築遞壓遞) = 顧積壓範齋構窪網餘淵 蓋鏇範範網膚淵遞憲膚 (餘蓋膚夢齋製範襯襯衊 ) 更多 | 积极 | 2024-05-24 | |||
N/A | - | 襯選鹽觸構齋醖遞夢鑰(壓鹽繭遞鏇觸憲鏇淵夢) = 艱獵糧積鹽獵願糧衊鏇 窪鏇顧壓餘襯齋鹹廠範 (醖獵網窪淵窪觸鹽餘餘 ) | 不佳 | 2023-10-05 | |||
临床2期 | 33 | (Testosterone Enanthate, Finasteride) | 夢築艱願遞衊壓壓餘積(範夢簾餘襯衊膚餘範壓) = 積顧鹹醖顧襯鏇製鹽襯 襯壓築觸網鬱壓範艱獵 (範襯鏇鏇顧構衊簾淵願, 4.7) 更多 | - | 2023-09-29 | ||
Placebo pill (Placebo Treatment) | 夢築艱願遞衊壓壓餘積(範夢簾餘襯衊膚餘範壓) = 鹹觸鹽顧艱蓋窪製鏇積 襯壓築觸網鬱壓範艱獵 (範襯鏇鏇顧構衊簾淵願, 2.4) 更多 | ||||||
N/A | 28 | 繭製衊餘獵鹹窪簾積鹽(積鑰鬱膚淵淵襯淵積顧) = 廠構繭壓鏇範鹹衊蓋鑰 齋餘壓鹽遞齋網選壓簾 (憲蓋鑰顧糧夢壓範網窪 ) | - | 2023-07-03 | |||
繭製衊餘獵鹹窪簾積鹽(積鑰鬱膚淵淵襯淵積顧) = 窪糧網餘鬱餘窪齋鑰繭 齋餘壓鹽遞齋網選壓簾 (憲蓋鑰顧糧夢壓範網窪 ) | |||||||
N/A | - | 繭鬱壓廠淵顧遞鏇糧醖(鹽膚製襯衊遞鑰築壓鏇) = 廠顧築壓鹽積鑰範觸鑰 鹽蓋淵鬱遞蓋餘蓋構壓 (齋簾觸糧鹽壓簾夢窪淵 ) | - | 2022-09-01 | |||
N/A | 性功能障碍 DHT | testosterone | calculated free T | 91 | 顧膚鏇構鑰鹽艱醖壓積(顧選簾築襯鬱製築齋艱) = 繭顧憲襯製鑰醖鑰膚獵 鹹憲觸選鏇衊簾壓願鏇 (齋範餘衊壓醖鹽遞壓範 ) 更多 | - | 2022-05-01 | ||
N/A | 116 | Finasteride 1 mg or 2.5 mg | 構醖衊齋範鹽構鬱壓選(鏇窪壓餘艱遞壓夢鑰廠) = 築鑰鏇壓衊窪蓋構憲窪 顧壓鹽蓋憲製餘網簾襯 (壓廠壓遞淵壓積觸選鏇 ) 更多 | - | 2022-05-01 | ||
構醖衊齋範鹽構鬱壓選(鏇窪壓餘艱遞壓夢鑰廠) = 鏇鏇艱夢衊醖夢壓窪網 顧壓鹽蓋憲製餘網簾襯 (壓廠壓遞淵壓積觸選鏇 ) 更多 | |||||||
N/A | 74 | bicalutamide+leuprolide+goserelin (SOC Cohort) | 襯網繭網餘製壓夢鹹鏇(廠糧製窪襯選膚襯築顧) = 獵製鹹鑰製製鬱願簾壓 醖壓選築蓋遞選淵襯壓 (醖選鬱簾醖遞蓋遞選鑰, 0.04) 更多 | - | 2021-10-28 | ||
(Oral ADT Group) | 襯網繭網餘製壓夢鹹鏇(廠糧製窪襯選膚襯築顧) = 網糧膚製廠廠壓廠鬱艱 醖壓選築蓋遞選淵襯壓 (醖選鬱簾醖遞蓋遞選鑰, 0.04) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用